<SEC-DOCUMENT>0001157523-18-000500.txt : 20180306
<SEC-HEADER>0001157523-18-000500.hdr.sgml : 20180306
<ACCEPTANCE-DATETIME>20180306075648
ACCESSION NUMBER:		0001157523-18-000500
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180305
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180306
DATE AS OF CHANGE:		20180306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLINA HEALTHCARE INC
		CENTRAL INDEX KEY:			0001179929
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				134204626
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31719
		FILM NUMBER:		18668647

	BUSINESS ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
		BUSINESS PHONE:		5624353666

	MAIL ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51768551.htm
<DESCRIPTION>MOLINA HEALTHCARE, INC. 8-K
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: business wire
    Document created using EDGARfilings PROfile 4.3.3.2
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div style="TEXT-ALIGN: left">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 100%; HEIGHT: 3px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Washington, D.C. 20549</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 10%; HEIGHT: 1px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">FORM 8-K</div>

<div style="TEXT-ALIGN: center">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 10%; HEIGHT: 1px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Report</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): March 6, 2018 (March 5, 2018)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 10%; HEIGHT: 1px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">MOLINA HEALTHCARE, INC.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="zd874f1c198d2467da0b6d741a1162e73" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</div>
</td>
<td style="WIDTH: 34%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1-31719</div>
</td>
<td style="WIDTH: 33.36%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">13-4204626</div>
</td>
</tr>

<tr>
<td style="WIDTH: 33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</div>
</td>
<td style="WIDTH: 34%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Commission File Number)</div>
</td>
<td style="WIDTH: 33.36%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(I.R.S. Employer Identification No.)</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 10%; HEIGHT: 1px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">200 Oceangate, Suite 100, Long Beach, California 90802</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Address of principal executive offices)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code:<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> (562) 435-3666</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: justify"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font><font style="FONT-SIZE: 6pt" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: justify"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font><font style="FONT-SIZE: 6pt" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: justify"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font><font style="FONT-SIZE: 6pt" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font><font style="FONT-SIZE: 6pt" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div>&#160;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 16.75pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z6e0042a1df254d3eb63d0c5f4e0dbb2e" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45%">
<div>&#160;</div>
</td>
<td style="WIDTH: 47%">
<div>Emerging growth company</div>
</td>
<td style="WIDTH: 8%">
<div>&#9744;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 45%">
<div>&#160;</div>
</td>
<td style="WIDTH: 47%">
<div>&#160;</div>
</td>
<td style="WIDTH: 8%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td colspan="2">
<div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</div>
</td>
<td style="WIDTH: 8%">&#9744;</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 26.5pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 8.01.&#160; Other Events.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">On March 6, 2018, the Company announced that on March 5, 2018,&#160;it priced a synthetic exchange transaction with a limited number of holders (the &#8220;Noteholders&#8221;) of its 1.625% Convertible Senior Notes due 2044 (the &#8220;1.625% Notes&#8221;) pursuant to which the Company has agreed to repurchase from the Noteholders an aggregate of $96,785,000 principal amount of the 1.625% Notes and simultaneously issue to the Noteholders an aggregate of 1,768,177 shares of its common stock registered under the Company&#8217;s Registration Statement on Form S-3, Registration No. 333-204558, filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended</font>.&#160; <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">A copy of the press release is attached hereto as Exhibit 99.1, the text of which is incorporated herein by reference.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The opinion of the Company&#8217;s counsel as to the legality of the common stock to be sold to the Noteholders is filed as Exhibit 5.1 to this Current Report on Form 8-K.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01.&#160; Financial Statements and Exhibits.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(d)</font><font style="FONT-SIZE: 5.14pt" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Exhibits:</font></div>

<div>&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z59ddeb464c7049c2ae42ca83617ac8f5" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">No.</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">5.1</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">Opinion of Boutin Jones Inc.</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">23.1</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">Consent of Boutin Jones Inc. (included in Exhibit 5.1)</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">99.1</div>
</td>
<td style="WIDTH: 91.35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Press release of Molina Healthcare, Inc., issued March 6, 2018, regarding the pricing of its synthetic exchange transaction</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div>&#160;</div>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z39ec9229b37c4fe9a38d5a158a1a67ae" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="3">MOLINA HEALTHCARE, INC.</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 47%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: March 6, 2018</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 2%; VERTICAL-ALIGN: top">By:</td>
<td style="BORDER-BOTTOM: #000000 2px solid; FONT-STYLE: italic; VERTICAL-ALIGN: top" colspan="2">/s/ Jeff D. Barlow</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 47%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Jeff D. Barlow</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 47%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Chief Legal Officer and Secretary</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<div>&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="zb7dad16dc3664980b0bba1da9bdc7805" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">No.</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top"><a href="a51768551ex5_1.htm">5.1</a></td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom"><a href="a51768551ex5_1.htm">Opinion of Boutin Jones Inc.</a></td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top"><a href="a51768551ex5_1.htm">23.1</a></td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom"><a href="a51768551ex5_1.htm">Consent of Boutin Jones Inc. (included in Exhibit 5.1)</a></td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 91.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.65%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><a href="a51768551ex99_1.htm">99.1</a></div>
</td>
<td style="WIDTH: 91.35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><a href="a51768551ex99_1.htm">Press release of Molina Healthcare, Inc., issued March 6, 2018, regarding the pricing of its synthetic exchange transaction</a></div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>a51768551ex5_1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: business wire
    Document created using EDGARfilings PROfile 4.3.3.2
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: right; FONT-WEIGHT: bold">Exhibit 5.1</div>

<div>&#160;</div>

<div><img src="logo.jpg"></div>

<div>
<div>&#160;</div>

<div>&#160;</div>

<div><br>
 &#160;</div>

<div>March 5, 2018</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Molina Healthcare, Inc.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">200 Oceangate, Suite 100</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Long Beach, CA 90802</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Ladies and Gentlemen:</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">This opinion is furnished to you in connection with the prospectus supplement dated the date hereof (the &#8220;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Prospectus Supplement</u></font>&#8221;), to the prospectus dated May&#160;29, 2015, included in the Registration Statement on Form S-3, Registration No. 333-204558, filed by Molina Healthcare, Inc., a Delaware corporation (the &#8220;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Company</u></font>&#8221;), with the Securities and Exchange Commission (the &#8220;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Commission</u></font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Securities Act</u></font>&#8221;), with respect to the sale by the Company to the Purchasers (as defined below) of 1,768,177 shares of the Company&#8217;s common stock (the &#8220;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Shares</u></font>&#8221;), $0.001 par value per share, pursuant to the Share Purchase Agreement, dated as of March 5, 2018 (the &#8220;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Share Purchase Agreement</u></font>&#8221;), by and among the Company and the institutional investors named on Schedules A attached thereto (the &#8220;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Purchasers</u></font>&#8221;).</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In connection with this opinion, we have examined such documents and such matters of fact and law that we have deemed necessary for the purpose of rendering the opinion set forth herein.&#160; In such examination, we have assumed without verification (a)&#160;the authenticity of original documents and the genuineness of all signatures, (b)&#160;the conformity to originals of all documents submitted to us as certified or photostatic copies, (c)&#160;the legal capacity of all natural persons and (d)&#160;the truth, accuracy and completeness of the information, representations and warranties contained in the records, documents, instruments and certificates examined by us.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Based upon the foregoing, and subject to the assumptions, qualifications and limitations set forth herein, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued by the Company against payment therefor in accordance with the terms of the Share Purchase Agreement (or as otherwise agreed by the Company and the Purchasers), the Shares will be validly issued, fully paid and non-assessable.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The opinion set forth above is limited to the General Corporation Law of the State of Delaware, and we express no opinion with respect to the laws of any other jurisdiction.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
</div>

<div>&#160;</div>

<div><img src="logo.jpg"></div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Molina Healthcare, Inc.</div>

<div style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 5, 2018</div>

<div style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Page 2</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We hereby consent to the filing of this opinion with the Commission as an exhibit to a Current Report on Form 8-K dated March 6, 2018 in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our firm&#8217;s name therein and in the Prospectus Supplement under the caption &#8220;Legal Matters&#8221;.&#160; In giving such consent, we do not admit we are included in the category of persons whose consent is required under Section&#160;7 of the Securities Act or the rules and regulations promulgated thereunder.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Very truly yours,</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">/s/ Boutin Jones Inc.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Boutin Jones Inc.</div>

<div><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a51768551ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: business wire
    Document created using EDGARfilings PROfile 4.3.3.2
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: right; FONT-WEIGHT: bold">Exhibit 99.1</div>

<div><br>
<p style="TEXT-ALIGN: center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><b>Molina Healthcare Announces Pricing of Synthetic Exchange Transaction</b></font> </p>

<p>LONG BEACH, Calif.--(BUSINESS WIRE)--March 6, 2018--Molina Healthcare, Inc. (NYSE: MOH) (the &#8220;Company&#8221;) today announced that on March 5, 2018, it priced a synthetic exchange transaction with a limited number of holders (the &#8220;Noteholders&#8221;) of its 1.625% Convertible Senior Notes due 2044 (the &#8220;1.625% Notes&#8221;) pursuant to which the Company has agreed to repurchase from the Noteholders an aggregate of $96,785,000 principal amount of the 1.625% Notes (collectively, the &#8220;Note Repurchases&#8221;) and simultaneously issue to the Noteholders an aggregate of 1,768,177 shares (the &#8220;Shares&#8221;) of its common stock (collectively, the &#8220;Share Issuances&#8221; and, together with the Note Repurchases, the &#8220;Transactions&#8221;) in privately negotiated transactions. SunTrust Robinson Humphrey, Inc. acted as Sole Exchange Agent and Financial Advisor to the Company for the Transactions. </p>

<p>On a net basis, the Company will not receive any proceeds from the Transactions and will pay customary fees and expenses in connection therewith. Therefore, the Transactions will not have a material impact on the Company&#8217;s cash position. </p>

<p>This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the Shares and shall not constitute an offer, solicitation or sale in any state or jurisdiction where such offer, solicitation or sale is prohibited. </p>

<p><b>About Molina Healthcare</b> </p>

<p>Molina Healthcare, Inc., a FORTUNE 500 company, provides managed health care services under the Medicaid and Medicare programs and through the state insurance marketplaces. Through its locally operated health plans, Molina Healthcare serves approximately 4.5 million members. For more information about Molina Healthcare, please visit our website at molinahealthcare.com. </p>

<p><i><b>Cautionary Statement under the Private Securities Litigation Reform Act</b>: This press release contains &#8220;forward-looking statements,&#8221; including statements related to the Note Repurchases and Share Issuances, which are subject to risks and uncertainties, including, without limitation, risks related to whether the Company will consummate the Transactions on the expected terms, or at all, and market and other general economic conditions. A discussion of the risk factors facing the Company can be found in its annual report on Form 10-K for the year ended December 31, 2017, in its Form 10-Q quarterly reports, in its Form 8-K current reports, and in its other reports and filings with the SEC. These reports can be accessed on the SEC&#8217;s website at </i><u>www.sec.gov</u><i>. The Company undertakes no obligation to release any revisions to any forward-looking statements.</i> </p>

<p>CONTACT:<br>
Molina Healthcare, Inc.<br>
Ryan Kubota, 562-435-3666<br>
Investor Relations<br>
</p>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Y 1L# 2(  A$! Q$!_\0
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MQ!&PKL1=_P""8_[.OQ"_98_9"T'P?\3O%@\7>*+*:>4S)<272:? [YBM5FD
M>4(O.6 V[RBY1%)\Q_X*6_M]?'#]B7X>^(_%6A_!SPMJG@W0WM(AXDO/%?F<
MS^5'N>P6*.3:+B3RN)B3@-A03CL_^"1O[5GB_P#;3_8PTSX@^-O[+&M:MJNH
M1A-.MC;V\,,5PR(BJ68X4 C)8DX&23S6BE!UM+WL>'B,%G=+@V,IJE]3=9--
M.$JG.X7LW%MJT=6I6DKI/30^FZ*_,7_@IS_P6 _:)_8?T[1(+KX-^"?!S>*O
MM<>FZC=>(V\0AS!LWGRXDM_+<"6,@.64Y/WL$5ZYK7[4O[2G[4WPVT*?]GGP
MOX3M]'DTR![SQWXTWVEOK=T8QYO]FV:@R^2'SB>:,1R9/EJ5 D9_6(W:5[^A
MR2\.,UIX2ACZ\Z4*-9R2FZL'!<NCO*+:O?113<G9^[H[?;U<M\:?@IX5_:)^
M&>I>#O&VBVGB+PQK'E?;=/N=WE7'ERI-'G:0?EDC1A@]5%?E;>_\%E?VF/\
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MR?\ ",G4- _X2CQ5KMNCM']JE#3Q6EI$Y4E5V3,=IP2A21_,OVU_VK/VS?\
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MGAA6M/#T>N>*=!E@B^XFGPK=2PQGV62WMOQ45Z%XRB5O^#K6$8X_M&T;'O\
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MJY#F..\/L/0P=&4YT<14]I%+WH>[O);I=V]%U/;_ /@OF1_PZ;^*O^]H^/\
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M2!TW.D:@^HA7TJC^SM8V]S_P=T>+V=$8VVHZK-"2/N2'0%4D>^'<?B:^V/\
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MMJI!'UKV&B@Q3:=UN>(>#_B1>_#VUE@T#]FWQ_H<,[!I(]//A>V60CH2$U0
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M(;.,'K0)2DDTGHSSK_AHKQ;_ -$)^*__ ('>&_\ Y;4?\-%>+?\ HA/Q7_\
M [PW_P#+:O2?#7BC3?&>B0:GH^H6.JZ;= M!=V<ZSP3 $@E74E3R".#VK*\)
M?%_PEX_U6>QT+Q1X=UJ^MD,DUO8:E#<RQ*#@EE1B0,D#)'4T$G%_\-%>+?\
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=00,)"@[5Z7110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
